Dr. Michael Abramoff, MD, PhD | Source | Founder and Executive Chairman at IDx

It's key that autonomous AI applications are thoroughly validated and developed in a clinically safe and explainable way that builds trust with patients and clinicians. Safety needs to be the number one concern for responsible AI companies. The ADA’s inclusion of our technology in its Standards of Care marks a significant move toward mainstream adoption of autonomous AI in clinical care. Our early customers are visionary leaders who foresaw that autonomous AI would one day become a standard of care for diabetic retinopathy screening, and taking that leap is paying off for them. Already, health systems that are using IDx-DR have experienced significant improvements in accessibility, efficiency and compliance rates, unleashing massive potential for cost savings and improved patient outcomes.